Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ANB | Ann: Ongoing Disclosure Notice - Watson | 04/07/25 | 0 | 85 | |||
|
|||||||
ANB | Ann: ANZ NZ Leadership team changes | 26/06/25 | 0 | 61 | |||
|
|||||||
ANB | Ann: Tim Horgan formally commences as GM Talent & Culture | 30/05/25 | 0 | 94 | |||
|
|||||||
ANB | Ann: ANZ NZ Leadership team changes | 19/05/25 | 0 | 131 | |||
|
|||||||
ANB | Ann: Change of Directors on ANZ New Zealand Board | 16/05/25 | 0 | 89 | |||
|
|||||||
ANB | Ann: ANZ Bank New Zealand Ltd ("ANB") -Trading to resume 10:15am | 08/05/25 | 0 | 71 | |||
|
|||||||
ANB | Ann: ANZ Disclosure Statement - Six months ended 31 March 2025 | 08/05/25 | 0 | 94 | |||
|
|||||||
ANB | Ann: APS 330 Pillar 3 Disclosure at 31 March 2025 | 08/05/25 | 0 | 115 | |||
|
See All Discussions